Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II clofarabine + cytarabine + liposomal doxorubicin in pediatric relapsed/refractory acute leukemia
2011-004893-28Phase 2Completed
- Sponsor
- Azienda Ospedaliera O.I.R.M. - S. Anna
- Start
- Mar 2012
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine, cytarabine and pegylated liposomal doxorubicin in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), sponsored by Azienda Ospedaliera O.I.R.M. - S. Anna. Primary endpoints: Overall response rate, Complete remission rate and 1 more. Started Mar 2012; status: completed.
02
Drugs
clofarabinecytarabinepegylated liposomal doxorubicin
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2011-004893-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004893-28.